Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

ABSTRACT: This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and checkpoint inhibitor relapsed tumors

DISEASE(S): Carcinoma,Triple Negative Breast Neoplasms,Non Small Cell Lung Cancer,Carcinoma, Renal Cell,Colorectal Cancer Metastatic,Colorectal Neoplasms,Triple Negative Breast Cancer,Bladder Cancer,Gastroesophageal Cancer,Renal Cell Carcinoma,Breast Neoplasms,Msi-h

PROVIDER: 2292184 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Immune Re-sensitization in Checkpoint Inhibitor Refractory and Relapsed Cancers with Plinabulin, Radiation and Immune Checkpoint Blockade

Project description:Immune Re-sensitization in Checkpoint Inhibitor Refractory and Relapsed Cancers with Plinabulin, Radiation and Immune Checkpoint Blockade

| PRJNA1078290 | ENA

Immune Re-sensitization in Checkpoint Inhibitor Refractory and Relapsed Cancers with Plinabulin, Radiation and Immune Checkpoint Blockade

Project description:Plinabulin exerts immunomodulatory activity through guanine-nucleotide-exchange-factor (GEF)-H1 activation, particularly in antigen-presenting cells. Here we demonstrate that radiation (RT) potentiates plinabulin-induced dendritic cell (DC) maturation, and when combined with immune-checkpoint-inhibitors (ICI), triggers an abscopal antitumor response via increased tumor-infiltrating CD86+ DCs and CD8+ T-cells. Nonclinical findings were translated in a phase 1 basket study (ClinicalTrial.org: NCT04902040) in patients with ICI-relapsed/refractory cancers. Plinabulin treatment after RT initiation plus ICI was safe and achieved an encouraging disease-control-rate (DCR) of 54% (3/13 partial response [PR] and 4/13 stable disease [SD]) in out-of-field unirradiated lesions; Enduring and 2/2 PR responses were seen in Hodgkin's lymphoma patients who had progressed after 12- or 16-prior lines of therapy. Responding PR+SD subjects had significant increases in peripheral blood proinflammatory monocytes, and activated DCs, and GEF-H1 induction in immune cells, T-cell clonal expansion, and intratumoral immune activation and GEF-H1 induction in DC subsetsactivation . These promising preliminary results provide the rationale for using this triple combination approach (RT/plinabulin/ICIdefine therapies?) in post-ICI-failure settings in future confirmatory trials.

2026-06-10 | GSE256118 | GEO

Impact of PD-L1 overexpression on immune checkpoint inhibitor efficacy in triple-negative breast cancer using a 4T1 murine model.

Project description:Bulk RNA sequencing was performed to investigate transcriptomic changes in 4T1 tumors treated with anti-PD-L1 therapy. Tumors were derived from 4T1 control and PD-L1-overexpressing cells injected into mice, followed by IgG or anti-PD-L1 treatment. Gene expression analysis revealed distinct immune-related pathway alterations, with reduced immune activation in PD-L1-overexpressing tumors. Differentially expressed genes suggested an immunosuppressive tumor microenvironment, potentially contributing to resistance to anti-PD-L1 therapy. These findings provide insights into the molecular mechanisms underlying immune checkpoint inhibitor response in triple-negative breast cancer.

2025-03-28 | GSE292013 | GEO

Immune checkpoint inhibitor-induced colitis

Project description:Immune checkpoint inhibitor-induced colitis

| PRJNA857579 | ENA

Distinct Cellular Mechanisms Underlie Chemotherapies and Their Combinations with PD-L1 Checkpoint Inhibitor in Triple-Negative Breast Cancer [TNBC]

Project description:Distinct Cellular Mechanisms Underlie Chemotherapies and Their Combinations with PD-L1 Checkpoint Inhibitor in Triple-Negative Breast Cancer [TNBC]

| PRJNA1108722 | ENA

Inhibiting CXCR4 Reduces Immunosuppressive Effects of Myeloid cells in Breast Cancer Immunotherapy

Project description:The goal of this experiment is to understand effects of combining CXCR4 inhibitor balixafortide with an anti-PD-1 immune checkpoint inhibitor on response to therapy in a mouse model of triple-negative breast cancer.

2025-04-16 | GSE282065 | GEO

Phase II Study of Immune Checkpoint Blockade with Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Project description:To address the role of immune dysregulation in AML, we conducted a phase II study of high-dose cytarabine followed by pembrolizumab 200 mg IV on day 14 to examine whether programmed death-1 inhibition improves clinical responses in relapsed/refractory (R/R) AML. Overall responders could receive pembrolizumab maintenance up to two years. Among thirty-seven patients enrolled, the overall response rate, composite complete remission rate (CRc; primary endpoint), and median overall survival (OS) were 46%, 38% and 11.1 months, respectively. Patients with refractory/early relapse and those receiving treatment as first salvage had encouraging outcomes (median OS 13.2 and 11.3 months, respectively). Grade >3 immune-related adverse events were rare (14%) and self-limiting. Patients who achieved CRc had a higher frequency of progenitor exhausted CD8+ T-cells in the bone marrow prior to treatment and a non-significant increase in baseline T-cell diversity.

2021-09-09 | GSE183415 | GEO

Combined oncolytic adenovirus DNX-2401 and anti-PD-checkpoint inhibitor pembrolizumab for recurrent glioblastoma

Project description:Combined oncolytic adenovirus DNX-2401 and anti-PD-checkpoint inhibitor pembrolizumab for recurrent glioblastoma

| PRJNA942342 | ENA

Phase II Study of Immune Checkpoint Blockade with Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Project description:Phase II Study of Immune Checkpoint Blockade with Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

| PRJNA760534 | ENA

RAGE Inhibitor TTP488 (Azeliragon) Reduces Metastasis in Triple-Negative Breast Cancer

Project description:RAGE Inhibitor TTP488 (Azeliragon) Reduces Metastasis in Triple-Negative Breast Cancer

| PRJNA884681 | ENA